Analysts think HAE stock price could increase by 44%
Oct 01, 2024, 11:25 AM
-10.40%
What does HAE do
Haemonetics, headquartered in Boston, develops hematology products to enhance patient care and reduce healthcare costs, employing 3,657 staff. Its solutions span plasma collection, blood management, and surgical technologies.
11 analysts think HAE stock price will increase by 44.03%. The current median analyst target is $115.77 compared to a current stock price of $80.38. The lowest analysts target is $85.85 and the highest analyst target is $131.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
